Prosecution Insights
Last updated: April 19, 2026

Examiner: LANDAU, SHARMILA GOLLAMUDI

Tech Center 1600 • Art Units: 1600 1611 1645 1651 1653 1655

This examiner grants 8% of resolved cases

Performance Statistics

8.3%
Allow Rate
-51.7% vs TC avg
191
Total Applications
+3.9%
Interview Lift
1547
Avg Prosecution Days
Based on 168 resolved cases, 2023–2026

Rejection Statute Breakdown

5.6%
§101 Eligibility
15.8%
§102 Novelty
40.4%
§103 Obviousness
20.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16863187 EQUOL-CONTAINING EXTRACT, METHOD FOR PRODUCTION THEREOF, METHOD FOR EXTRACTION OF EQUOL, AND EQUOL-CONTAINING FOOD Final Rejection OTSUKA PHARMACEUTICAL CO., LTD.
17603695 PLANT-DERIVED SCAFFOLDS FOR GENERATION OF SYNTHETIC ANIMAL TISSUE Final Rejection Wisconsin Alumni Research Foundation
18583611 NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS Final Rejection CMPD Licensing, LLC
18134210 PRODUCT COMPRISING PROBIOTICS AND ISOMALTULOSE AND METHOD OF ITS PRODUCTION Non-Final OA Bluestone Pharma GmbH
17999858 COMPOSITION FOR PURIFYING RESERVOIRS FROM CYANOBACTERIA AND GREEN ALGAE Final Rejection LYSTERRA LLC
17915306 PHARMACEUTICAL COMPOSITION COMPRISING NEW LACTOBACILLUS PLANTARUM KC3 STRAIN AND LEONURUS JAPONICUS EXTRACT AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING RESPIRATORY DISEASE AND USE THEREOF Non-Final OA CKD BIO CORPORATION
17774545 PREPARATIONS FOR ENHANCED BIOCONTROL Final Rejection AREVO AB
17719042 INHALABLE IMATINIB FORMULATION Final Rejection Inaya Therapeutics, Inc.
17710552 EXTRACELLULAR MATRIX STRUCTURES Final Rejection Elutia Med LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month